Teclistamab versus real-world physician's choice of therapy in triple-class exposed relapsed/refractory multiple myeloma.
J Comp Eff Res
; 12(6): e220186, 2023 06.
Article
in En
| MEDLINE
| ID: mdl-37114426
ABSTRACT
Aim:
We compared the effectiveness of teclistamab versus real-world physician's choice of therapy (RWPC) in triple-class exposed relapsed/refractory multiple myeloma. Materials &methods:
MajesTEC-1 eligibility criteria were applied to the RWPC cohort. Baseline covariate imbalances were adjusted using inverse probability of treatment weighting. Overall survival, progression-free survival and time to next treatment were compared.Results:
After inverse probability of treatment weighting, baseline characteristics were similar between cohorts (teclistamab, n = 165; RWPC, n = 364 [766 observations]). Teclistamab treated patients had numerically better overall survival (hazard ratio [HR] 0.82 [95% CI 0.59-1.14]; p = 0.233) and significantly greater progression-free survival (HR 0.43 [0.33-0.56]; p < 0.0001) and time to next treatment (HR 0.36 [0.27-0.49]; p < 0.0001) versus the RWPC cohort.Conclusion:
Teclistamab offered clinical benefit over RWPC in triple-class exposed relapsed/refractory multiple myeloma.Key words
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Physicians
/
Multiple Myeloma
/
Antineoplastic Agents
Limits:
Humans
Language:
En
Journal:
J Comp Eff Res
Year:
2023
Document type:
Article
Affiliation country:
Estados Unidos